Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
https://www.zacks.com/stock/news/2226283/drug-biotech-stock-q4-earnings-due-on-feb-15-alny-bpmc-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2226283
Feb 14, 2024 - Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
0
What Analyst Projections for Key Metrics Reveal About Ultragenyx (RARE) Q4 Earnings
https://www.zacks.com/stock/news/2224655/what-analyst-projections-for-key-metrics-reveal-about-ultragenyx-rare-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2224655
Feb 12, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Ultragenyx (RARE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
0
Pinterest: Acceleration Is Rare In This Environment
https://seekingalpha.com/article/4669422-pinterest-acceleration-is-rare-in-this-environment?source=feed_all_articles
Feb 11, 2024 - Pinterest continues to see strong user growth and ad revenue growth, fueling massive boosts in profitability. Learn why PINS stock is a Buy.
0
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
https://www.zacks.com/stock/news/2223449/ultragenyx-rare-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2223449
Feb 08, 2024 - Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Rare Stock Picks In January 2024 - From 45 Discerning Analysts
https://seekingalpha.com/article/4667578-rare-stock-picks-in-january-2024-from-45-discerning-analysts?source=feed
Feb 05, 2024 - In our monthly Rare Stock Picks series, we're highlighting January 2024 investment picks. Click here for the list of January 2024 Buy recommendations.
0
Lynas Rare Earths had talks with MP Materials, though `not ongoing' (update)
https://seekingalpha.com/news/4062368-lynas-rare-earths-says-had-talks-with-mp-materials-though-not-ongoing-report?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Feb 03, 2024 - Lynas Rare Earths denies ongoing talks with MP Materials for a potential deal, according to Bloomberg report, addressing media speculation.
0
Tyra gets FDA Rare Pediatric Disease status for dwarfism drug
https://seekingalpha.com/news/4061754-tyra-gets-fda-rare-pediatric-disease-status-for-dwarfism-drug?source=feed_sector_healthcare
Feb 01, 2024 - Tyra Biosciences (TYRA) said the FDA has granted Rare Pediatric Disease Designation to its drug candidate TYRA-300 in the treatment of dwarfism. Read more here.
0
Inovio upgraded at Oppenheimer on rare disease therapy
https://seekingalpha.com/news/4058683-inovio-stock-upgraded-at-oppenheimer?source=feed_sector_healthcare
Jan 25, 2024 - Oppenheimer upgrades Inovio Pharmaceuticals (INO), citing its investigational therapy for recurrent respiratory papillomatosis (RRP). Read more here.
0
Arafura Rare Earths Limited (ARAFF) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4664830-arafura-rare-earths-limited-araff-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Jan 24, 2024 - Arafura Rare Earths Limited (OTCPK:ARAFF) Q4 2023 Earnings Conference Call January 24, 2024 9:00 PM ETCompany ParticipantsMark Southey - ChairmanGavin...
0
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214518
Jan 23, 2024 - Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
0